Protox Appoints Dr. Martin Gleave as Chair of Clinical Advisory Board



    VANCOUVER, Sept. 18 /CNW/ - Protox Therapeutics Inc. (TSX-V:PRX) today
announced the appointment of Dr. Martin Gleave MD, FRCSC, FACS, as the
Chairman of its Clinical Advisory Board (Urology). Dr. Gleave brings to Protox
a wealth of clinical and research experience in the field of prostate disease
and will be instrumental in providing strategic guidance as the company
advances its clinical programs for both localized prostate cancer and BPH
(enlarged prostate).
    "Dr. Gleave is an internationally acclaimed researcher, surgeon and
urologist and we are extremely pleased to have attracted a thought leader of
his caliber to our Company," said Dr. Fahar Merchant, President and CEO of
Protox. "Dr. Gleave's leadership, knowledge and vast clinical experience will
be invaluable as we continue to advance the PRX302 clinical programs towards
commercialization."
    Dr. Gleave is a Professor in the Department of Urologic Sciences at the
University of British Columbia, Director of the Prostate Center at Vancouver
General Hospital, Chair of the Genito-Urinary Tumour Group at BC Cancer
Agency, and is appointed as a Consultant Urologist for the Department of
Urology at the University of Washington. He has published more than 200
peer-reviewed papers, and currently has more that $40M in peer reviewed
funding. He is a recipient of many awards, including the National Cancer
Institute of Canada's prestigious William Rawls Award for contributions to
cancer control in Canada, Distinguished University Scholar designation by the
University of British Columbia, and in 2005, was awarded the BC Leadership
Chair in Prostate Cancer Research.
    Dr. Gleave is the Founder and CSO of OncoGenex, a private clinical-stage
biotechnology company focused on developing new cancer therapies that address
treatment resistance in cancer patients. He is active in clinical trials
across Canada and is Chairman of the National Cancer Institute of Canada GU
Clinical Trials Group, and Chairman of the Canadian Uro-Oncology Group.

    About Protox

    Protox Therapeutics is a leader in advancing novel, targeted protein
toxin therapeutics for the treatment of cancer and other proliferative
diseases. The company is actively developing two distinct but complementary
platforms, INxin(TM) and PORxin(TM), and currently has four clinical programs
in development. A Phase 2a clinical trial into the use of PRX321 (INxin) for
the treatment of primary brain cancer has been completed and the drug has
received Fast Track Designation and Orphan Drug Status from the US FDA. In
addition, a Phase 1 trial has been completed for PRX321 to treat patients with
renal cell carcinoma and non-small cell lung cancer. Patient enrollment has
been completed for a Phase 1 clinical trial into the use of PRX302 (PORxin)
for the treatment of localized prostate cancer. A Phase 1 clinical study of
PRX302 for the treatment of benign prostatic hyperplasia (enlarged prostate)
is ongoing.

    NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENT OF THIS
    RELEASE. THE TSX VENTURE EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE
    ADEQUACY OR ACCURACY OF THIS RELEASE.

    Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Protox'
current beliefs as well as assumptions made by and information currently
available to Protox and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
of this press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Protox in its public securities filings; actual
events may differ materially from current expectations. Protox disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.





For further information:

For further information: James Beesley, Director, Investor Relations,
Protox Therapeutics, (604) 484-0975, jbeesley@protoxtherapeutics.com; Michael
Moore, Investor Relations, Equicom Group, (416) 815-0700 x 241,
mmoore@equicomgroup.com

Organization Profile

Sophiris Bio, Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890